Clinical Trial Update: Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) [Phase 3]

View source ↗

Summary

ECZTRA 2, a Phase 3 trial of tralokinumab monotherapy for moderate-to-severe atopic dermatitis, has completed with results posted in 2020. The sponsor is LEO Ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Tralokinumab (tralokinumab)

Snippet

Sponsor: LEO Pharma | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2020-08-24